Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
Thomas B. Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021
Cited by 642 works. doi:10.1016/s1470-2045(21)00152-2
Authors
- Thomas B. Powles
- Tibor Csőszi
- Mustafa Özgüroğlu
- Nobuaki Matsubara
- Lajos Géczi
- Susanna Yee-Shan Cheng
- Yves Fradet
- Stéphane Marie. Oudard
- Christof Vulsteke
- Rafael Morales‐Barrera
- Aude Fléchon
- Seyda Gulenay Gunduz
- Yohann Loriot
- Alejo Rodríguez‐Vida
- Ronac Mamtani
- Evan Y. Yu
- Kijoeng Nam
- Kentaro Imai
- Blanca Homet Moreno
- Ajjai Shivaram Alva
References
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
- Comparative analysis of two rates
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
- Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer